NEU Phase 2 trial shows significant improvements in Pitt Hopkins 27/05/24 PRICE SENSITIVE download Created with Sketch. 461.4KB Share NEU Trading Halt 23/05/24 PRICE SENSITIVE download Created with Sketch. 187.22KB Share NEU DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m 09/05/24 PRICE SENSITIVE download Created with Sketch. 4.23MB Share NEU Q1 2024 quarterly activity and cash flow report 24/04/24 PRICE SENSITIVE download Created with Sketch. 554.54KB Share NEU Trofinetide accepted for Priority Review by Health Canada 23/04/24 PRICE SENSITIVE download Created with Sketch. 283.58KB Share NEU Neuren reports profit of $157 million for 2023 29/02/24 PRICE SENSITIVE download Created with Sketch. 928.21KB Share NEU Appendix 4E and 2023 full year accounts 29/02/24 PRICE SENSITIVE download Created with Sketch. 713.93KB Share NEU DAYBUE net sales US$87.1 million in Q4 2023 28/02/24 PRICE SENSITIVE download Created with Sketch. 451.14KB Share NEU Comment on research report 16/02/24 PRICE SENSITIVE download Created with Sketch. 219.15KB Share NEU Pause in Trading 16/02/24 PRICE SENSITIVE download Created with Sketch. 115.14KB Share NEU Q4 2023 Appendix 4C Cash Flow Report 31/01/24 PRICE SENSITIVE download Created with Sketch. 154.86KB Share NEU Q4 2023 quarterly activity report 31/01/24 PRICE SENSITIVE download Created with Sketch. 639.68KB Share NEU Completion of enrolment in Neuren's Angelman P2 trial 20/12/23 PRICE SENSITIVE download Created with Sketch. 205KB Share NEU Investor presentation, 18 December 2023 18/12/23 PRICE SENSITIVE download Created with Sketch. 2.97MB Share NEU P2 trial shows significant improvements in Phelan-McDermid 18/12/23 PRICE SENSITIVE download Created with Sketch. 723.12KB Share NEU Trading Halt 14/12/23 PRICE SENSITIVE download Created with Sketch. 198.45KB Share NEU Neuren completes enrolment in Pitt Hopkins Phase 2 trial 05/12/23 PRICE SENSITIVE download Created with Sketch. 188.42KB Share NEU DAYBUE net sales US$66.9 million in Q3 2023 03/11/23 PRICE SENSITIVE download Created with Sketch. 209.5KB Share NEU Q3 2023 quarterly activity and cash flow report 20/10/23 PRICE SENSITIVE download Created with Sketch. 556.7KB Share NEU S&P DJI Announces September 2023 Quarterly Rebalance 01/09/23 PRICE SENSITIVE download Created with Sketch. 121.59KB Share NEU Half Yearly Report and Accounts 28/08/23 PRICE SENSITIVE download Created with Sketch. 485.54KB Share NEU Q2 2023 quarterly activity and cash flow report 31/07/23 PRICE SENSITIVE download Created with Sketch. 545.93KB Share NEU Neuren receives US$100m for expanded DAYBUE agreement 27/07/23 PRICE SENSITIVE download Created with Sketch. 162.94KB Share NEU Neuren and Acadia expand global partnership for trofinetide 14/07/23 PRICE SENSITIVE download Created with Sketch. 179.35KB Share NEU Neuren completes enrolment in Phelan-McDermid Phase 2 trial 30/06/23 PRICE SENSITIVE download Created with Sketch. 128.16KB Share NEU Neuren opens first site in US for Prader-Willi Phase 2 trial 28/06/23 PRICE SENSITIVE download Created with Sketch. 272.4KB Share NEU Neuren receives US$40m milestone payment 07/06/23 PRICE SENSITIVE download Created with Sketch. 122.47KB Share NEU Q1 2023 quarterly activity and cash flow report 28/04/23 PRICE SENSITIVE download Created with Sketch. 331.52KB Share NEU DAYBUE (trofinetide) launched in US - Neuren earns US$40m 18/04/23 PRICE SENSITIVE download Created with Sketch. 330.95KB Share NEU FDA approves Daybue - the first treatment for Rett syndrome 13/03/23 PRICE SENSITIVE download Created with Sketch. 258.83KB Share NEU Neuren reports 2022 full-year results 24/02/23 PRICE SENSITIVE download Created with Sketch. 177.83KB Share NEU Appendix 4E and 2022 full year accounts 24/02/23 PRICE SENSITIVE download Created with Sketch. 458.57KB Share NEU Q4 2022 quarterly activity and cash flow report 31/01/23 PRICE SENSITIVE download Created with Sketch. 278.86KB Share NEU Prader-Willi syndrome IND for NNZ-2591 approved by FDA 23/01/23 PRICE SENSITIVE download Created with Sketch. 149.69KB Share NEU Neuren submits IND & first patients complete Phase 2 trials 23/12/22 PRICE SENSITIVE download Created with Sketch. 285.67KB Share NEU Q3 2022 quarterly activity and cash flow report 27/10/22 PRICE SENSITIVE download Created with Sketch. 409.29KB Share NEU Neuren receives US$10 million milestone payment 20/10/22 PRICE SENSITIVE download Created with Sketch. 147.13KB Share NEU Rett Syndrome NDA accepted for Priority Review by FDA 13/09/22 PRICE SENSITIVE download Created with Sketch. 231.46KB Share NEU S&P DJI Announces September 2022 Quarterly Rebalance 02/09/22 PRICE SENSITIVE download Created with Sketch. 134KB Share NEU Half Yearly Report and Accounts 24/08/22 PRICE SENSITIVE download Created with Sketch. 338.87KB Share NEU Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS 08/08/22 PRICE SENSITIVE download Created with Sketch. 178.95KB Share NEU Quarterly Activities/Appendix 4C Cash Flow Report 29/07/22 PRICE SENSITIVE download Created with Sketch. 349.07KB Share NEU Acadia submits Rett Syndrome New Drug Application to the FDA 19/07/22 PRICE SENSITIVE download Created with Sketch. 309.46KB Share NEU Neuren commences Phase 2 trial of NNZ-2591 in Angelman 12/07/22 PRICE SENSITIVE download Created with Sketch. 154.47KB Share NEU Neuren appoints Chief Medical Officer in United States 08/07/22 PRICE SENSITIVE download Created with Sketch. 150.09KB Share NEU Quarterly Activities/Appendix 4C Cash Flow Report 29/04/22 PRICE SENSITIVE download Created with Sketch. 276.23KB Share NEU FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial 25/03/22 PRICE SENSITIVE download Created with Sketch. 151.55KB Share NEU FDA approval for Phelan-McDermid IND and Phase 2 trial 23/03/22 PRICE SENSITIVE download Created with Sketch. 152.68KB Share NEU Ethics approval for Angelman Phase 2 trial in Australia 11/03/22 PRICE SENSITIVE download Created with Sketch. 152.94KB Share NEU S&P DJI Announces March 2022 Quarterly Rebalance 04/03/22 PRICE SENSITIVE download Created with Sketch. 175.5KB Share NEU FDA approval for Angelman IND and Phase 2 trial 25/02/22 PRICE SENSITIVE download Created with Sketch. 154.3KB Share NEU 2021 Results - a transformational year for Neuren 24/02/22 PRICE SENSITIVE download Created with Sketch. 175.8KB Share NEU Preliminary Final Report and 2021 Full Year Accounts 24/02/22 PRICE SENSITIVE download Created with Sketch. 486.79KB Share NEU Q4 2021 quarterly activity and cash flow report 31/01/22 PRICE SENSITIVE download Created with Sketch. 339.96KB Share NEU Positive topline results from Phase 3 trial in Rett syndrome 07/12/21 PRICE SENSITIVE download Created with Sketch. 174.6KB Share NEU Q3 2021 quarterly activity and cash flow report 28/10/21 PRICE SENSITIVE download Created with Sketch. 274.92KB Share NEU Neuren receives feedback on IND for Phelan-McDermid syndrome 21/10/21 PRICE SENSITIVE download Created with Sketch. 148.11KB Share NEU US patent to 2034 granted for Neuren's NNZ-2591 in autism 11/10/21 PRICE SENSITIVE download Created with Sketch. 148.04KB Share NEU $3.3 million raised from oversubscribed SPP 06/10/21 PRICE SENSITIVE download Created with Sketch. 125.58KB Share NEU Feedback on Angelman IND and submission of Pitt Hopkins IND 01/10/21 PRICE SENSITIVE download Created with Sketch. 149.68KB Share NEU IND application submitted for NNZ-2591 in Phelan-McDermid 21/09/21 PRICE SENSITIVE download Created with Sketch. 150.63KB Share NEU Share Purchase Plan Offer Booklet 17/09/21 PRICE SENSITIVE download Created with Sketch. 219.19KB Share NEU New patent issued to 2032 for Neuren's trofinetide in Brazil 16/09/21 PRICE SENSITIVE download Created with Sketch. 154.69KB Share NEU Investor Presentation, 13 September 2021 13/09/21 PRICE SENSITIVE download Created with Sketch. 1.66MB Share NEU Proposed issue of securities - NEU 13/09/21 PRICE SENSITIVE download Created with Sketch. 35.17KB Share NEU Placement to accelerate NNZ-2591 across 4 indications 13/09/21 PRICE SENSITIVE download Created with Sketch. 177.69KB Share NEU Trading Halt 09/09/21 PRICE SENSITIVE download Created with Sketch. 193.13KB Share NEU FDA grants Orphan Drug designation for Prader-Willi syndrome 03/09/21 PRICE SENSITIVE download Created with Sketch. 152.03KB Share NEU Angelman IND and Ethics applications submitted for NNZ-2591 01/09/21 PRICE SENSITIVE download Created with Sketch. 149.97KB Share NEU R&D Tax Incentive Advance Overseas Finding Approval 30/08/21 PRICE SENSITIVE download Created with Sketch. 150.81KB Share NEU Half Yearly Report and Accounts 25/08/21 PRICE SENSITIVE download Created with Sketch. 345.88KB Share NEU Phase 3 enrolment successfully completed, results in Q4 2021 05/08/21 PRICE SENSITIVE download Created with Sketch. 214.02KB Share NEU Q2 2021 quarterly activity and cash flow report 30/07/21 PRICE SENSITIVE download Created with Sketch. 323.96KB Share NEU Positive FDA meetings enable INDs for three Phase 2 trials 01/06/21 PRICE SENSITIVE download Created with Sketch. 150.7KB Share NEU New patent issued to 2032 for Neuren's trofinetide in Canada 29/04/21 PRICE SENSITIVE download Created with Sketch. 155.06KB Share NEU Quarterly report and cash flow statement for Q1 2021 22/04/21 PRICE SENSITIVE download Created with Sketch. 263.27KB Share NEU S&P DJI Announces March 2021 Quarterly Rebalance 12/03/21 PRICE SENSITIVE download Created with Sketch. 183.24KB Share NEU Neuren successfully completes manufacturing for Phase 2 10/03/21 PRICE SENSITIVE download Created with Sketch. 183.13KB Share NEU Neuren approaching transforming milestones in 2021 24/02/21 PRICE SENSITIVE download Created with Sketch. 163.7KB Share NEU Preliminary Final Report and 2020 full year accounts 24/02/21 PRICE SENSITIVE download Created with Sketch. 508.05KB Share NEU Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline 16/02/21 PRICE SENSITIVE download Created with Sketch. 225KB Share NEU Successful Phase 1 trial for Neuren's NNZ-2591 15/02/21 PRICE SENSITIVE download Created with Sketch. 153.49KB Share NEU Quarterly report and cash flow statement for Q4 2020 29/01/21 PRICE SENSITIVE download Created with Sketch. 204.13KB Share NEU European Commission grants 3 NNZ-2591 Orphan designations 11/01/21 PRICE SENSITIVE download Created with Sketch. 143.44KB Share NEU Positive opinion for all 3 Orphan applications in Europe 07/12/20 PRICE SENSITIVE download Created with Sketch. 145.2KB Share NEU Approval received for final stage of NNZ-2591 clinical trial 19/11/20 PRICE SENSITIVE download Created with Sketch. 129.76KB Share NEU Quarterly report and cash flow statement for Q3 2020 29/10/20 PRICE SENSITIVE download Created with Sketch. 265.24KB Share NEU Neuren initiates manufacture of NNZ-2591 for Phase 2 trials 22/09/20 PRICE SENSITIVE download Created with Sketch. 142.98KB Share NEU Half Yearly Report and Accounts 26/08/20 PRICE SENSITIVE download Created with Sketch. 274.21KB Share NEU Q2 2020 Activity Report and Cash Flow Report 27/07/20 PRICE SENSITIVE download Created with Sketch. 193.97KB Share NEU Proposed issue of Securities - NEU 29/06/20 PRICE SENSITIVE download Created with Sketch. 33.15KB Share NEU Neuren successfully completes $20m capital raising 29/06/20 PRICE SENSITIVE download Created with Sketch. 131.12KB Share NEU Trading Halt 25/06/20 PRICE SENSITIVE download Created with Sketch. 160.11KB Share NEU Temporary enrolment pause ended in Phase 3 trial in the US 16/06/20 PRICE SENSITIVE download Created with Sketch. 242.24KB Share NEU Neuren announces changes to leadership team 27/05/20 PRICE SENSITIVE download Created with Sketch. 132.46KB Share NEU Neuren commences first clinical trial for NNZ-2591 07/05/20 PRICE SENSITIVE download Created with Sketch. 121.9KB Share NEU Appendix 4C - quarterly 17/04/20 PRICE SENSITIVE download Created with Sketch. 55.99KB Share NEU Q1 2020 Activity Report 17/04/20 PRICE SENSITIVE download Created with Sketch. 131.81KB Share NEU First patent in Israel granted for trofinetide 02/04/20 PRICE SENSITIVE download Created with Sketch. 118.28KB Share NEU Temporary pause in new enrolments for LAVENDER trial in US 24/03/20 PRICE SENSITIVE download Created with Sketch. 198.24KB Share
$19.39
(20min delay)
